Plasma renin activity and plasma prorenin are not suppressed in elderly hypertensive patients.

1995 ◽  
Vol 8 (4) ◽  
pp. 105A
Author(s):  
P TRENKWALDER
1978 ◽  
Vol 24 (7) ◽  
pp. 1202-1204 ◽  
Author(s):  
F Fyhrquist ◽  
L Puutula

Abstract Plasma renin activity was measured in parallel in Na2EDTA-contained plasma samples after storage at -20, 4, and 24 degrees C, and in the lyophilized state. In peripheral venous plasma from 22 hypertensive patients, the activity (range, 0.08-46.7 microgram/liter per hour) remained stable during three days of storage at 4 degrees C, but decreased to a variable extent when plasma was kept at 24 degrees C: in one day by 9.2%, two days by 25.6%, and three days by 74.0%. Values were the same for samples handled at room temperature and chilled to 4 degrees C within 3 h and parallel samples immediately cooled in an icebath and kept at 4 degrees C. Freezing (-20 degrees C) and thawing of plasma was associated with a 22% mean increase in activity (range, 0-83%). Lyophilization resulted in a smaller increase of plasma renin activity (mean 12%, range 0-46%). Blood for renin analysis need not be cooled immediately, but must be cooled to 4 degrees C within 2-3 h. It then is stabe for at least three days. Freezing or lyophilization appears to be associated with some cold activation of "prorenin."


2009 ◽  
Vol 55 (5) ◽  
pp. 867-877 ◽  
Author(s):  
Duncan J Campbell ◽  
Juerg Nussberger ◽  
Michael Stowasser ◽  
A H Jan Danser ◽  
Alberto Morganti ◽  
...  

AbstractBackground: Measurement of plasma renin is important for the clinical assessment of hypertensive patients. The most common methods for measuring plasma renin are the plasma renin activity (PRA) assay and the renin immunoassay. The clinical application of renin inhibitor therapy has thrown into focus the differences in information provided by activity assays and immunoassays for renin and prorenin measurement and has drawn attention to the need for precautions to ensure their accurate measurement.Content: Renin activity assays and immunoassays provide related but different information. Whereas activity assays measure only active renin, immunoassays measure both active and inhibited renin. Particular care must be taken in the collection and processing of blood samples and in the performance of these assays to avoid errors in renin measurement. Both activity assays and immunoassays are susceptible to renin overestimation due to prorenin activation. In addition, activity assays performed with peptidase inhibitors may overestimate the degree of inhibition of PRA by renin inhibitor therapy. Moreover, immunoassays may overestimate the reactive increase in plasma renin concentration in response to renin inhibitor therapy, owing to the inhibitor promoting conversion of prorenin to an open conformation that is recognized by renin immunoassays.Conclusions: The successful application of renin assays to patient care requires that the clinician and the clinical chemist understand the information provided by these assays and of the precautions necessary to ensure their accuracy.


1978 ◽  
Vol 55 (s4) ◽  
pp. 301s-303s ◽  
Author(s):  
S. F. Wong ◽  
M. I. Mitchell ◽  
V. Robson ◽  
R. Wilkinson

1. Plasma renin activity, response to saralasin and exchangeable sodium have been measured in 43 patients with early renal disease. 2. Blood pressure was directly proportional to plasma renin activity. However, mean plasma renin activity was lower in patients with renal disease than in normal controls. 3. Blood pressure fell in response to saralasin infusion in proportion to the pre-infusion plasma renin activity. 4. Exchangeable sodium in hypertensive patients with renal disease did not exceed that in normotensive patients in contrast to earlier reports. Discrepancies may arise from the difficulty in interpreting measured exchangeable sodium in relation to body build.


1982 ◽  
Vol 63 (2) ◽  
pp. 121-125 ◽  
Author(s):  
S. Swart ◽  
R. F. Bing ◽  
J. D. Swales ◽  
H. Thurston

1. Plasma renin activity, body weight and blood pressure were measured before and after 7 days' treatment with bendrofluazide in ten hypertensive subjects. They were then treated with bendrofluazide alone (5 mg daily) for a minimum of 3 years. The diuretic was then discontinued and the measurements were repeated before and again after 7 days with bendrofluazide. The results were compared with those obtained before chronic treatment with the diuretic. 2. Chronic diuretic treatment was associated with a persistent and progressive rise in plasma renin activity, that fell promptly to pretreatment levels when diuretics were discontinued. This was associated with significant weight gain but no immediate significant rise in blood pressure. 3. When acutely challenged with bendrofluazide the patients showed a greater increase in plasma renin activity on the second occasion than on the first. Three out of five patients with an initially subnormal response had normal responses after chronic diuretic treatment. 4. Chronic diuretic treatment increased the responsiveness of the juxtaglomerular apparatus in some hypertensive patients. 5. Classification of hypertensive patients into renin subgroups may be influenced by previous therapy, even when that therapy has been discontinued for 4 weeks. In particular ‘low renin hypertension’ may be masked by recent use of diuretics, as shown by three of the five patients in this subgroup in the present study.


Sign in / Sign up

Export Citation Format

Share Document